DelveInsight’s “Acute Pain Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Acute Pain market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Acute Pain drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Acute Pain treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Acute Pain: An Overview
Pain is an uncomfortable sensation that usually signals an injury or illness and tells the body that something is wrong. It is a sensory symptom of tissue damage or disorder that can be either acute or chronic. The International Association for the Study of Pain (IASP) defines acute pain as sudden pain that starts sharp or intense and is a warning sign of disease or threat to the body. It is caused by injury, surgery, illness, trauma, or painful medical procedures and generally lasts from a few minutes to less than 6 months. Acute pain usually disappears whenever the underlying cause is treated or healed. Nearly all cases of chronic pain begin as acute pain. Depending on the type of injury, acute pain may last for weeks or even months. Acute pain can vary significantly and can be categorized into two main types: spontaneous insult or trauma and elective or planned procedures.
The goal of pain treatment is not necessarily zero pain but a level of tolerable pain that allows the patient maximum physical and emotional functioning with the lowest risk of side effects, and progression to chronic pain. The pharmacological therapies include analgesics that are further segregated into opioids, non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, corticosteroids, anesthetics, etc. Acute pain is also managed by the use of benzodiazepines, muscle relaxants, antidepressants, alpha-2 agonists, gamma-aminobutyric agonists, and cannabinoids.
Further, non-pharmacological therapies include acupuncture, psychological approaches (cognitive behavioral therapy, mindfulness-based stress reduction), chiropractic manipulation, physical therapy, transcutaneous electrical stimulation, massage therapy, exercise, and other complementary and alternative medicine therapies (CAM).
Acute Pain Market Key Facts
-
In 2022, the United States reported ~51,756,000 surgery cases, ~54,418,000 trauma cases, and ~53,681,000 cases of other medical illnesses.
-
In 2022, ~85% of the acute pain incident cases were diagnosed in the United States, which was estimated to be around 94,529,000.
-
Postoperative and trauma pain were found to contribute the most cases in the total diagnosed acute pain cases in the United States, with more than 80% of cases put together.
-
In 2022, the incidence rate of acute pain was estimated to be ~80%, ~70%, and ~40% for the cases of surgery, trauma, and other medical illnesses, in the United States.
-
In the United States, for severity-specific cases of acute pain, most of the cases were found to be mild and moderate, with severe acute pain cases accounting for only ~15% of the diagnosed acute pain incident cases in 2022.
-
In 2022, ~50% and ~100% of the mild and moderate acute pain diagnosed cases, respectively, were treated in the United States, which was estimated to be around 77,268,000.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Acute Pain pipeline therapies. It also thoroughly assesses the Acute Pain market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Acute Pain drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Acute Pain Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Acute Pain epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Acute Pain epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Acute Pain Epidemiology, Segmented as –
-
Total Incident Cases of Acute Pain in the 7MM (2019–2032)
-
Total Treated Cases of Acute Pain in the 7MM (2019–2032)
-
Total Severity-specific Cases of Acute Pain in the 7MM (2019–2032)
-
Total Type-specific Cases of Acute Pain in the 7MM (2019–2032)
-
Total Diagnosed Incident Cases of Acute Pain in the 7MM (2019–2032)
Acute Pain Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Acute Pain market or expected to be launched during the study period. The analysis covers the Acute Pain market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares Acute Pain drugs based on their sale and market share.
The report also covers the Acute Pain pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Acute Pain companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Acute Pain Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/acute-pain-market
Acute Pain Therapeutics Analysis
The treatment pattern currently consists of different approaches classified into pharmacologic and nonpharmacological therapies. The pharmacological therapies include analgesics that are further segregated into opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, corticosteroids, anesthetics, etc. Acute pain is also managed by the use of benzodiazepines, muscle relaxants, antidepressants, alpha-2 agonists, gamma-aminobutyric agonists, and cannabinoids.
Further, nonpharmacological therapies include acupuncture, psychological approaches (cognitive behavioral therapy, mindfulness-based stress reduction), chiropractic manipulation, physical therapy, transcutaneous electrical stimulation, massage therapy, exercise, and other complementary and alternative medicine therapies (CAM). All these involve the concept known as multimodal analgesia.
Several major pharma and biotech companies are developing therapies for Acute Pain. Currently, Neumentum is leading the therapeutics market with its Acute Pain drug candidates in the most advanced stage of clinical development.
Acute Pain Companies in the Therapeutics Market Include:
Neumentum, CGeneTech, Algomedix, TREMEAU PHARMACEUTICALS, Vertex Pharmaceuticals, Kures, Inc., Jiangsu Hengrui Medicine Co., SiteOne Therapeutics, Mylan Specialty, LP, Viatris Inc., Tetra Bio-Pharma, Scilex Pharmaceuticals, Inc., Hyloris Pharmaceuticals, AFT Pharmaceuticals, Formosa Pharmaceuticals, Concentric Analgesics, Vivozon, Vertex Pharmaceuticals, Taiwan Liposome Company (TLC), Medical Developments International (MVP), Neumentum Pharmaceuticals, Charleston Laboratories, AcelRx Pharmaceuticals, Teikoku Pharma USA, PainReform, Nevakar, and many others.
Emerging and Marketed Acute Pain Therapies Covered in the Report Include:
-
NTM-001: Neumentum
-
CGT 1507: CGeneTech
-
TRPA1 Antagonist: Algomedix
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/acute-pain-market
Acute Pain Therapeutics Landscape
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Acute Pain Competitive Intelligence Analysis
4. Acute Pain Market Overview at a Glance
5. Acute Pain Disease Background and Overview
6. Acute Pain Patient Journey
7. Acute Pain Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Acute Pain Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute Pain Unmet Needs
10. Key Endpoints of Acute Pain Treatment
11. Acute Pain Marketed Therapies
12. Acute Pain Emerging Drugs and Latest Therapeutic Advances
13. Acute Pain Seven Major Market Analysis
14. Attribute Analysis
15. Acute Pain Market Outlook (In US, EU5, and Japan)
16. Acute Pain Companies Active in the Market
17. Acute Pain Access and Reimbursement Overview
18. KOL Views on the Acute Pain Market
19. Acute Pain Market Drivers
20. Acute Pain Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/acute-pain-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Uncover the pulse of the MedTech industry through our in-depth market research services. Gain a strategic advantage with actionable insights into trends, competition, and emerging technologies. Elevate your business decisions and stay ahead in this dynamic medical devices landscape: MedTech Market Research
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology